Respiratory Medicine, Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK.
BMC Pulm Med. 2011 Apr 7;11:16. doi: 10.1186/1471-2466-11-16.
The immune modulating properties of statins may benefit smokers with asthma. We tested the hypothesis that short-term treatment with atorvastatin improves lung function or indices of asthma control in smokers with asthma.
Seventy one smokers with mild to moderate asthma were recruited to a randomized double-blind parallel group trial comparing treatment with atorvastatin (40 mg per day) versus placebo for 4 weeks. After 4 weeks treatment inhaled beclometasone (400 μg per day) was added to both treatment arms for a further 4 weeks. The primary outcome was morning peak expiratory flow after 4 weeks treatment. Secondary outcome measures included indices of asthma control and airway inflammation.
At 4 weeks, there was no improvement in the atorvastatin group compared to the placebo group in morning peak expiratory flow [-10.67 L/min, 95% CI -38.70 to 17.37, p = 0.449], but there was an improvement with atorvastatin in asthma quality of life score [0.52, 95% CI 0.17 to 0.87 p = 0.005]. There was no significant improvement with atorvastatin and inhaled beclometasone compared to inhaled beclometasone alone in outcome measures at 8 weeks.
Short-term treatment with atorvastatin does not alter lung function but may improve asthma quality of life in smokers with mild to moderate asthma.
Clinicaltrials.gov identifier: NCT00463827.
他汀类药物具有免疫调节作用，可能有益于哮喘患者中的吸烟者。我们检验了这样一个假设，即短期阿托伐他汀治疗可改善哮喘患者的肺功能或哮喘控制指标。
招募了 71 名轻中度哮喘吸烟者，进行了一项随机双盲平行组试验，比较了阿托伐他汀（每天 40 毫克）与安慰剂治疗 4 周的疗效。4 周后，在两个治疗组中均加用吸入布地奈德（每天 400μg），再治疗 4 周。主要结局是治疗 4 周后的清晨最大呼气流量。次要结局指标包括哮喘控制和气道炎症指标。
与安慰剂组相比，阿托伐他汀组在清晨最大呼气流量方面，4 周时无明显改善[-10.67L/min，95%CI-38.70 至 17.37，p=0.449]，但阿托伐他汀组的哮喘生活质量评分有所改善[0.52，95%CI0.17 至 0.87，p=0.005]。与单独使用吸入布地奈德相比，加用阿托伐他汀和吸入布地奈德在 8 周时的结局指标中无明显改善。
短期阿托伐他汀治疗不能改变肺功能，但可能改善轻中度哮喘患者的哮喘生活质量。
Clinicaltrials.gov 标识符：NCT00463827。
